No increase in subtrochanteric or diaphyseal femur fractures was seen with denosumab use compared with bisphosphonates in 4 ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Adults with osteoporosis prescribed the antiresorptive denosumab were no more likely to sustain an atypical femur fracture ...

Denosumab and bisphosphonates exhibit similar efficacy and safety profiles for preventing fractures among patients with osteoporosis. Evidence from a large population-based cohort study in South Korea ...

Credit: Shutterstock. Treatment with Prolia was associated with greater reductions in the overall relative risk across various fracture types. Treatment with denosumab (Prolia ®) was associated with ...

Hypercalcemia of malignancy (HCM) is the most common metabolic complication seen in patients with cancer, and is associated with a high degree of morbidity and mortality. It affects an estimated 2%–30 ...

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

Patients on dialysis who take denosumab face a 36% higher risk for major cardiovascular adverse events than patients who take oral bisphosphonates, according to a study published Jan. 6 in Annals of ...

A major UK-based study has found that denosumab, a widely used osteoporosis medication, does not raise the risk of atypical femur fractures compared with bisphosphonates over four years. The result ...

ANSWER: Denosumab (Prolia) is a treatment for osteoporosis that is normally given as an injection every six months. Among its ...